{
  "abstract": "On 01 August 2025, the UK became the first country in the world to offer the meningococcal B vaccine (4CMenB, Bexsero, GSK) for protection against gonorrhoea for those at high risk.1 In England, there were more than 70 000 gonorrhoea diagnoses in 2024, a threefold increase since 2012,2 and more than half were in gay, bisexual and other men who have sex with men (GBMSM).2",
  "authors": [
    {
      "affiliations": [
        "Immunisation Division, UK Health Security Agency, London, UK",
        "Centre for Neonatal and Paediatric Infection, City St George’s University of London, London, UK"
      ],
      "name": "Shamez N Ladhani"
    },
    {
      "affiliations": [
        "STI Division, UK Health Security Agency, London, England, UK"
      ],
      "name": "Helen Fifer"
    }
  ],
  "title": "The 2025 UK 4CMenB vaccine programme for GBMSM at high risk of gonorrhoea",
  "uid": "e6c17bb8-3530-5c69-9b8b-ca866f3c962b"
}